From Big Pharma to conservation: Chemist Tim Cernak applies drug design skills to save endangered species
By
Anna Gibbs
Solid neighbourhood-bakery energy. Trustworthy and warm.
Summary
Chemist Tim Cernak, after nearly two decades developing precision therapies for cancer, HIV, and diabetes at Merck, is now applying his pharmaceutical expertise to conservation. He aims to use his drug design skills to help save endangered species like Gila monsters and loggerhead sea turtles, shifting from human medicine to ecosystem health.
Key quotes
· 3 pulledIn 2018, after nearly two decades working in Big Pharma, chemist Tim Cernak was ready to put his skills to a new use.
For Merck, he'd developed precision therapies for cancer, HIV, and diabetes that could target disease while minimizing harm to healthy cells.
But as a lifelong nature lover, he was increasingly concerned about the health of ecosystems and wondered whether his expertise could help.
You might also wanna read
The costly failure of amyloid-beta drugs: A cautionary tale in pharmaceutical development
The article discusses drug classes that are perceived as failures after massive investment and clinical trials, using amyloid-beta drugs for
Colossal Biosciences Advances Artificial Womb Technology After Dire Wolf De-Extinction
Science start-up Colossal, known for its de-extinction efforts like bringing back dire wolves, is now pioneering artificial womb technology

Creative professionals share sustainable product swaps that combine good design with eco-consciousness
Creative Boom asked its community of designers, illustrators, and brand strategists about sustainable product swaps that genuinely feel like
Pharmaceutical LSD (MM120) Shows Promise in Treating Generalized Anxiety Disorder in UCSF Clinical Trials
Researchers at UCSF are testing MM120, a pharmaceutical form of LSD, as a treatment for generalized anxiety disorder (GAD). The treatment ha

Royal Danish Academy Showcases Sustainable Design Projects Including Wildlife-Habitat Maternity Clinic
The article showcases innovative design projects from the Royal Danish Academy, including a maternity clinic in India with cladding designed
NIH Halts Tuberculosis Research Over Unfounded 'Dangerous' Gain-of-Function Concerns
A UC Berkeley professor and NIH grant recipient describes how the NIH abruptly ordered them to stop their tuberculosis research, deeming it
